Rapid, Large-Scale Generation of Highly Pure Cytomegalovirus-Specific Cytotoxic T Cells for Adoptive Immunotherapy
- 1 February 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy & Stem Cell Research
- Vol. 12 (1) , 93-105
- https://doi.org/10.1089/152581603321210172
Abstract
Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific cytotoxic T cell (CTL) clones can restore immunity in allogeneic stem cell transplant recipients, providing protection against CMV disease. Current methods for selecting and expanding CMV-specific T cell clones are technically difficult, making adoptive T cell therapy impractical for routine clinical use. In this study, we describe a method for ex vivo generation and expansion of high-purity CMV-specific CTL using peptide-pulsed dendritic cells as antigen-presenting cells. Generation of CMV-specific CTL in numbers sufficient for clinical use in the time span of 4 weeks was accomplished in 6 of 8 CMV-seropositive donors. Examination of pp65 specificity by HLA/peptide tetramer staining demonstrated that a purity of greater than 95% peptide-specific cells could be obtained after two weekly stimulations and retained after further expansion for 3-4 weeks. Median expansion of total cell number was greater than 500-fold and expansion of peptide-specific CTL by tetramer staining was greater than 1.7 × 105-fold. Four weeks after initiating CTL culture, we were able to generate greater than 109 total cells that specifically lysed target cells loaded with CMV peptide and cells infected with CMV. This simple and rapid method for generating high-purity CMV-specific CTL for adoptive immunotherapy is currently being examined for routine clinical use for allogeneic stem cell transplantation.Keywords
This publication has 50 references indexed in Scilit:
- Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cellsTransplantation and Cellular Therapy, 2001
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- A Risk-Adapted Approach with a Short Course of Ganciclovir to Prevent Cytomegalovirus (CMV) Pneumonia in CMV-Seropositive Recipients of Allogeneic Bone Marrow TransplantsClinical Infectious Diseases, 1997
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytesJournal of Medical Virology, 1994
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992
- Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor‐Derived CMV‐Specific T Cell Clones Expanded In VitroaAnnals of the New York Academy of Sciences, 1991
- Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patientThe Lancet, 1991
- Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses.The Journal of Experimental Medicine, 1988
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986